课题基金 / 基金详情

The molecular basis of persistent HIV-specific CD4 T cell dysfunction

The molecular basis of persistent HIV-specific CD4 T cell dysfunction
HIV特异性CD4 T细胞持续功能障碍的分子基础
批准号：
408708
负责人：
Kaufmann Daniel E
金额：
$74.96万
依托单位：
Centre hospitalier de l'Universit de Montral (CHUM)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-09-01 至 2024-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=408708&lang=en
关键词：
Antiretroviral Therapy (Art) Antiviral Immunity Cd4 T Cell Gene Expression Hiv Immune Exhaustion Immune Reconstitution Systems Biology (-Omics Technologies) T Cell Programming Thelper Differentiation And Function

项目摘要

项目成果

Kaufmann Daniel E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Antiviral therapy (ART) that blocks replication of HIV has resulted in a remarkable improvement in the quality of life for people living with HIV/AIDS. However, specific white cells that recognize HIV, called T cells, remain incapable of effectively fight
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunovirological determinants of breakthrough COVID-19 disease in vaccinated or previously infected individuals
COVID-19 Variant Supplement - Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease
Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease
Influence of pre-existing HIV cross-reactive CD4 T cells on vaccine responses to new Env immunogens
海外基金